Research Papers
This database includes peer-reviewed publications authored by TB Alliance staff. Use the tags on the left to filter by subject, or search for a particular author or term using the search bar.
Tag: Moxifloxacin
Displaying 30 papers
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
Publication: Lancet Infectious Diseases
5/2024
Global adoption of 6-month drug-resistant TB regimens: Projected uptake by 2026
Publication: PLOS One
1/2024
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
Publication: International Journal of Tuberculosis and Lung Disease
3/2021
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial
Publication: The Lancet Respiratory Medicine
11/2019
Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations
Publication: BMC Infectious Diseases
9/2019
Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
Publication: Antimicrobial Agents and Chemotheraphy
4/2019
Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study
Publication: BMC Medicine
3/2018
Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fl uoroquinolones: results from a multicountry surveillance project
Publication: Zignol, Matteo, Anna Dean, and Natavan Alikhanova. "Population-based Resistance of Mycobacterium Tuberculosis." The Lancet (Published Online July 7, 2016 Http://dx.doi.org/10.1016/S1473-3099(16)30190-6):
7/2016
Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials
Publication: Phillips PPJ, Mendel CM, Burger DA, et al. Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials. BMC Medicine. 2016 Mar.14:19. doi: 10.1186/s12916-016-0565-y
3/2016
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant...
Publication: Dawson R, Diacon AH, Everitt D, et. al. Efficiency and safety of.... Lancet. 2015 May 2;385(9979):1738-47. doi: 10.1016/S0140-6736(14)62002-X.
5/2015
Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models
Publication: Li SY, Irwin SM, Converse PJ, Mdluli KE, Lenaerts AJ, Nuermberger EL. Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models. Antimicrob Agents Chemother. 2015 Jul;59(7):4026-30. doi: 10.1128/AAC.00105-15.
4/2015
Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis
Publication: Alffenaar JW, Gumbo T, Aarnoutse R. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2015 Feb 5;372(6):576. doi: 10.1056/NEJMc1414718#SA1.
2/2015
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis
Publication: New England Journal of Medicine
10/2014
Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
Publication: Gillespie SH, Crook AM, McHugh TD, et. al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014 Oct 23;371(17):1577-87. doi: 10.1056/NEJMoa1407426.
4/2014
Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen
Publication: Dutta NK, Alsultan A, Gniadek TJ, et. al. Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. Antimicrob Agents Chemother. 2013 Aug;57(8):3910-6. doi: 10.1128/AAC.00761-13.
8/2013
Early bactericidal activity of new drug regimens for tuberculosis - Authors' reply
Publication: Diacon AH, Donald PR, Mendel CM. Early bactericidal activity of new drug regimens for tuberculosis - Authors' reply. Lancet. 2013 Jan 12;381(9861):112-3. doi: 10.1016/S0140-6736(13)60042-2.
1/2013
In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters
Publication: Upton AM, Cho S, Yang TJ, et. al. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015 Jan;59(1):136-44. doi: 10.1128/AAC.03823-14.
6/2012
Moxifloxacin for tuberculosis
Publication: Mendel C, Springsklee M. Moxifloxacin for tuberculosis. Lancet Infect Dis. 2012 Mar;12(3):176-7; author reply 177-8. doi: 10.1016/S1473-3099(11)70351-6.
3/2012
New Drugs for the Treatment of Tuberculosis: Needs, Challenges, Promise, and Prospects for the Future
Publication: Lienhardt C, Raviglione M, Spigelman M, et. al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis. 2012 May 15;205 Suppl 2:S241-9. doi: 10.1093/infdis/jis034.
3/2012